Cancer-Associated Fibroblasts-Orchestrated Immune Remodeling as a Key Driver in Liver Cancer
- 1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- 2Department of Translational Research and New Surgical and Medical Technologies, University of Pisa, Pisa, Italy
Abstract
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) develop within a highly immunosuppressive tumor microenvironment (TME) characterized by chronic inflammation, extensive stromal remodeling, and impaired antitumor immunity. Among stromal components, cancer-associated fibroblasts (CAFs) have emerged as key regulators of tumor progression and immune homeostasis. This review provides an overview of CAF-mediated immune remodeling in primary liver cancers, with particular emphasis on CAF heterogeneity, CAF–immune cell interactions, and their impact on disease progression and therapeutic response. Increasing evidence indicates that CAFs orchestrate multiple aspects of the tumor immune microenvironment through the secretion of cytokines, chemokines, growth factors, and extracellular matrix components. These signals promote immune exclusion, suppress cytotoxic T-cell activity, and favor the accumulation of immunosuppressive cell populations, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Advances in single-cell and spatial transcriptomic technologies have revealed substantial CAF heterogeneity and identified distinct CAF subsets with specialized immunomodulatory functions. These findings have uncovered novel therapeutic opportunities, including CAF-targeted approaches, extracellular matrix normalization, and strategies aimed at reprogramming CAF plasticity. Overall, CAFs are central orchestrators of immune remodeling in liver cancer and contribute to the establishment of an immunosuppressive microenvironment that supports tumor progression and therapeutic resistance. Targeting CAF-driven stromal–immune interactions may enhance antitumor immunity and improve the efficacy of current and emerging immunotherapies in HCC and iCCA.
Related
- Immune–fibroblast ligand–receptor axes in post-infarction cardiac remodeling: convergent and divergent mechanisms compared with cancer-associated fibroblasts
- Cancer-associated fibroblasts and immune evasion in endometrial cancer: current evidence and therapeutic perspectives
- ANO6-mediated trogocytosis of cancer-associated fibroblasts promotes pancreatic cancer cell growth and immune suppression
- Bladder cancer immune microenvironment: immune-cell distribution, disease associations, treatment remodeling, and baseline immune features associated with treatment response and prognosis
- Microbiota-associated post-translational remodeling of immune cell states in gastrointestinal cancer
BibTeX
@article{porro2026cancerassociated,
title = {{Cancer-Associated Fibroblasts-Orchestrated Immune Remodeling as a Key Driver in Liver Cancer}},
author = {Nunzia Porro and Silvia Marri and Francesca Salani and Fabio Marra and Laura Gragnani and Alessandra Gentilini},
journal = {Oncology Research},
year = {2026},
month = oct,
doi = {10.32604/or.2026.083633},
url = {https://doi.org/10.32604/or.2026.083633},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cancer-Associated Fibroblasts-Orchestrated Immune Remodeling as a Key Driver in Liver Cancer
AU - Nunzia Porro
AU - Silvia Marri
AU - Francesca Salani
AU - Fabio Marra
AU - Laura Gragnani
AU - Alessandra Gentilini
PY - 2026
DA - 2026/10/28
JO - Oncology Research
DO - 10.32604/or.2026.083633
UR - https://doi.org/10.32604/or.2026.083633
AB - Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) develop within a highly immunosuppressive tumor microenvironment (TME) characterized by chronic inflammation, extensive stromal remodeling, and impaired antitumor immunity. Among stromal components, cancer-associated fibroblasts (CAFs) have emerged as key regulators of tumor progression and immune homeostasis. This review provides an overview of CAF-mediated immune remodeling in primary liver cancers, with particular emphasis on CAF heterogeneity, CAF–immune cell interactions, and their impact on disease progression and therapeutic response. Increasing evidence indicates that CAFs orchestrate multiple aspects of the tumor immune microenvironment through the secretion of cytokines, chemokines, growth factors, and extracellular matrix components. These signals promote immune exclusion, suppress cytotoxic T-cell activity, and favor the accumulation of immunosuppressive cell populations, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Advances in single-cell and spatial transcriptomic technologies have revealed substantial CAF heterogeneity and identified distinct CAF subsets with specialized immunomodulatory functions. These findings have uncovered novel therapeutic opportunities, including CAF-targeted approaches, extracellular matrix normalization, and strategies aimed at reprogramming CAF plasticity. Overall, CAFs are central orchestrators of immune remodeling in liver cancer and contribute to the establishment of an immunosuppressive microenvironment that supports tumor progression and therapeutic resistance. Targeting CAF-driven stromal–immune interactions may enhance antitumor immunity and improve the efficacy of current and emerging immunotherapies in HCC and iCCA.
SN - 0965-0407
SN - 1555-3906
ER -